ACADIA PHARMACEUTICALS INC. Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
ACADIA PHARMACEUTICALS INC. (ACAD) had Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss of $1.00 thousand as of 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss · last filed 2020-08-06
- 2020-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $1.00K.
- 2019-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $2.00K.
- 2019-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $14.00K.
- 2019-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $84.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss |
|---|---|
| 2020-06-30 | $1.00K 10-Q · filed 2020-08-06 |
| 2019-09-30 | $2.00K 10-Q · filed 2019-10-31 |
| 2019-06-30 | $14.00K 10-Q · filed 2019-08-01 |
| 2019-03-31 | $84.00K 10-Q · filed 2019-05-02 |
| 2018-12-31 | $214.00K 10-K · filed 2020-02-27 |
| 2018-09-30 | $129.00K 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |